Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a supplemental Biologics
License Application to the U.S. Food and Drug Administration (FDA) for
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
for the treatment of advanced non-small cell lung cancer (NSCLC).
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more